What is Chonluten?
Chonluten is a short, three-amino-acid peptide — a tripeptide — originally isolated from bronchial epithelial cells, the tissue that lines your airways. Because it comes from lung tissue, researchers classify it as a lung or bronchial bioregulator.
A bioregulator is a tiny peptide that acts like a molecular instruction — it carries a signal that helps specific tissues do their jobs more precisely. Chonluten belongs to a family of compounds developed and characterized by Professor Vladimir Khavinson starting in the 1970s, collectively called the Khavinson Peptides®. Each one was isolated from a specific organ and appears to target that same type of tissue. Chonluten's origin in bronchial cells is what makes it particularly interesting for respiratory research.[1]
Important note: Chonluten is a research compound only. It is not approved as a medicine and is not intended for human use outside of scientific study. Nothing here is medical advice.
How Chonluten Works
Think of your immune system like a volume dial. When bacteria or other threats show up, inflammatory signals turn the volume way up — sometimes too loud and for too long. That excess inflammation can damage healthy tissue. The body has built-in ways to quiet that signal back down, and Chonluten appears to help with exactly that process.
More specifically, lab research suggests Chonluten may influence the activity of immune cells called monocytes and macrophages. These are the frontline responders that release inflammatory proteins — called cytokines — when trouble is detected.[1]
One key cytokine is TNF, or tumor necrosis factor. It's a powerful alarm signal. Another is IL-6. Both are useful in short bursts, but harmful in excess. Chonluten has been observed, in cell studies, to reduce how much TNF and IL-6 monocytes and macrophages release when they're provoked by LPS — a molecule found on the surface of harmful bacteria.[1]
Researchers describe this as TNF tolerance — a controlled, deliberate quieting of the alarm rather than a complete shutdown. The immune system stays functional; it just doesn't overreact.[1]
What the Research Shows
The key published study on Chonluten used a well-established laboratory model: the THP-1 cell line, a type of human immune cell that can be transformed into either monocytes or macrophages in the lab. Researchers at the University G. d'Annunzio in Italy and the Saint Petersburg Institute of Bioregulation and Gerontology tested five Khavinson Peptides® side by side, including Chonluten.[1]
Here is what they found for Chonluten specifically:
- Reduced TNF production: When monocytes were exposed to LPS (a bacterial inflammatory trigger), Chonluten reduced how much TNF they released. This effect is linked to a natural mechanism called TNF tolerance, which damps down runaway inflammation.[1]
- Reduced IL-6 expression: Like the other peptides tested, Chonluten also helped reduce the expression of pro-inflammatory IL-6 in fully differentiated macrophages stimulated by LPS.[1]
- Less cell adhesion: When immune cells stick to blood vessel walls, that's an early step in inflammation. In this study, cells treated with the Khavinson Peptides® — including Chonluten — showed reduced adhesion to activated endothelial cells (the cells lining blood vessels).[1]
- Kinase activity: All five peptides, including Chonluten, increased tyrosine phosphorylation of certain cytoplasmic kinases — proteins that act as internal on/off switches in cells. This is part of how the peptides appear to influence cell behavior at a molecular level.[1]
These findings are promising, but it's critical to remember they come from in vitro (test tube / cell culture) research — not human clinical trials. More research is needed before any conclusions about human health can be drawn.
What Chonluten Is Being Studied For
Based on its origins in bronchial tissue and its observed effects on immune cells, Chonluten is primarily studied in the context of:
- Respiratory tissue biology — how bronchial epithelial cells age, regenerate, and respond to damage
- Inflammation regulation — understanding how peptides can modulate excessive immune responses[1]
- Biogerontology — the science of aging; many Khavinson Peptides® are studied as part of research into how tissues decline with age
- Innate immune function — specifically how monocytes and macrophages respond to microbial signals[1]
How Chonluten Is Dosed in Research
Dosing protocols for Chonluten in research settings vary depending on the model being studied — whether it's a cell culture, an animal model, or an early human study. Because no universal standard has been established, researchers typically refer to published protocols and adapt them to their specific model. For a structured overview of the concentrations and schedules that have appeared in the scientific literature, see the dosage chart on this page. You can also use the on-page calculator to work out volumes based on your reconstitution concentration. Always work within an approved research framework.
Mixing and Storing Chonluten
Chonluten is typically supplied as a lyophilized powder — that means it has been freeze-dried to remove water, making it stable for storage. To prepare it for research use, you reconstitute it by adding sterile bacteriostatic water slowly to the vial. Gently swirl — never shake vigorously — to dissolve the powder without degrading the peptide. Once reconstituted, store the solution in a refrigerator (around 2–8 °C / 36–46 °F) and use it within a few weeks, or freeze aliquots if longer storage is needed. Keep unmixed powder in a cool, dry, dark place. As with all research peptides, protect from repeated freeze-thaw cycles, heat, and direct light, all of which can break down the compound and reduce its integrity for study purposes.
Sources
- Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line. — International journal of molecular sciences, 2022. PMID 35408963.
EN
BR
ES
FR
DE
RU